Latest progress in tyrosine kinase inhibitors

descriptionPublicationkeyboard_double_arrow_right Article 15 Mar 2014 English Publisher:Impact Journals, LLCJournal:Oncotarget, volume 5, pages 1,157-1,161 (eissn: 1949-2553,

Copyright policy )

Authors: Tatiana V, Pospelova; Valery A, Pospelov;

doi: 10.18632/oncotarget.1836

pmid: 24727648

pmc: PMC4012733

Latest progress in tyrosine kinase inhibitors

- Summary
- Subjects
- Metrics

Abstract

Here we discuss the latest progress in development of some kinase inhibitors such as inhibitors of c-MET, LIM and Bcr-Abl kinases. Importantly, many oncogenic kinases signal via the mTOR pathway, suggesting a common target for drug combinations.

Related Organizations

Russian Academy of Science
Russian Federation
St Petersburg University
Russian Federation
Saint Petersburg State University (Санкт-Петербургский государственный университет)
Russian Federation
Russian Academy of Sciences
Russian Federation
Institute of Cytology
Russian Federation

Keywords

Neoplasms, TOR Serine-Threonine Kinases, NF-kappa B, Humans, Lim Kinases, Protein-Tyrosine Kinases, Proto-Oncogene Proteins c-met, Signal Transduction

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average